Success Metrics

Clinical Success Rate
67.9%

Based on 112 completed trials

Completion Rate
68%(112/165)
Active Trials
32(12%)
Results Posted
58%(65 trials)
Terminated
53(19%)

Phase Distribution

Ph phase_3
61
22%
Ph phase_4
35
13%
Ph early_phase_1
6
2%
Ph not_applicable
22
8%
Ph phase_1
51
18%
Ph phase_2
87
31%

Phase Distribution

57

Early Stage

87

Mid Stage

96

Late Stage

Phase Distribution262 total trials
Early Phase 1First-in-human
6(2.3%)
Phase 1Safety & dosage
51(19.5%)
Phase 2Efficacy & side effects
87(33.2%)
Phase 3Large-scale testing
61(23.3%)
Phase 4Post-market surveillance
35(13.4%)
N/ANon-phased studies
22(8.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

59.6%

112 of 188 finished

Non-Completion Rate

40.4%

76 ended early

Currently Active

32

trials recruiting

Total Trials

277

all time

Status Distribution
Active(35)
Completed(112)
Terminated(76)
Other(54)

Detailed Status

Completed112
Terminated53
unknown50
Withdrawn23
Recruiting21
Active, not recruiting11

Development Timeline

Analytics

Development Status

Total Trials
277
Active
32
Success Rate
67.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (2.3%)
Phase 151 (19.5%)
Phase 287 (33.2%)
Phase 361 (23.3%)
Phase 435 (13.4%)
N/A22 (8.4%)

Trials by Status

withdrawn238%
active_not_recruiting114%
terminated5319%
completed11240%
recruiting218%
unknown5018%
suspended41%
not_yet_recruiting31%

Recent Activity

Clinical Trials (277)

Showing 20 of 277 trialsScroll for more
NCT04316494Phase 4

Hydroxychloroquine in ANCA Vasculitis Evaluation

Terminated
NCT04381936Phase 3

Randomised Evaluation of COVID-19 Therapy

Recruiting
NCT05842174Phase 1

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

Recruiting
NCT02595346Phase 2

Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome

Terminated
NCT01480154Phase 1

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

Active Not Recruiting
NCT05518110Phase 2

PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer

Terminated
NCT04527549Phase 2

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Terminated
NCT05942911Phase 2

Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis

Terminated
NCT07343635Not Applicable

The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea

Recruiting
NCT04532346Early Phase 1

Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes

Recruiting
NCT05016297Phase 2

Efficacy and Safety of Baricitinib in Sjogren's Syndrome

Completed
NCT05799378Phase 3

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

Recruiting
NCT05041907Phase 2

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Recruiting
NCT04345692Phase 3

A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients

Terminated
NCT03598595Phase 1

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

Active Not Recruiting
NCT04201457Phase 1

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Active Not Recruiting
NCT04524702Phase 2

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Completed
NCT07352566Phase 4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not Yet Recruiting
NCT06971744Phase 2

Autophagy Maintenance (AUTOMAIN)

Recruiting
NCT05843188Phase 2

Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
277